Posted on 09/16/2024 4:38:41 AM PDT by Red Badger
In a phase 1 trial, the oral drug Amycretin helped individuals lose up to 13.1% of their body weight in three months by targeting key appetite-regulating hormones, presenting a potential breakthrough in tablet-form obesity treatments.
=============================================================================
Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued weight loss. While well-tolerated, further long-term studies are needed to evaluate its safety and efficacy.
Individuals who received a once-a-day oral weight loss drug had lost up to 13% of their body weight over three months, according to a recent presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September).
Amycretin, which is being developed by the Danish pharmaceutical company Novo Nordisk A/S, mimics the action of two peptide hormones in one single molecule.
Amycretin is both an amylin and glucagon-like peptide-1 (GLP-1) receptor agonist. Both of these play a key role in appetite regulation and feelings of hunger and have been shown to lead to weight loss.
Current Treatments and Study Design
Currently, GLP-1 based treatment options are mainly administered via injections, a delivery method also used for the amylin-based treatments undergoing clinical development. To date, there are no tablet-form treatment options targeting both of these biologies.
In a single-center, placebo-controlled, double-blinded phase 1 study, adult participants with a BMI of 25.0-39.9 kg/m2 without diabetes were randomized to receive amycretin or a placebo once-a-day for up to 12 weeks.
The study, which was conducted by Novo Nordisk A/S, and a clinical research unit in the US, consisted of single- and multiple ascending dose parts, where different doses of amycretin were tested orally: single-ascending dose (increasing from 1 mg a day to 25 mg)10-day multiple-ascending doses (investigating from 3 to 12 mg), and 12-week multiple-ascending doses (by introducing stepwise dose escalation, investigating from a start dose of 3 mg and up to a final dose of 2×50 mg).
In the first-in-human trial, amycretin appeared to have a safe and tolerable profile in line with the drug receptor classes. Side effects were mainly mild to moderate in severity and of gastrointestinal nature including nausea and vomiting.
Weight Loss Results
At the end of the trial, average weight loss was greater with amycretin than with the placebo. Participants taking amycretin 50 mg reduced their body weight by 10.4%, on average, within 12 weeks of treatment, while those taking amycretin 2x50mg, the maximum dose tested, achieved a body weight reduction of 13.1%. This compares to an average weight loss of 1.1% among those taking placebo during the same time.
Notably, at the end of the treatment period, weight loss had not reached a plateau for participants taking amycretin, indicating the potential for further weight loss with extended use.
The study’s authors conclude that daily oral amycretin treatment in adults with overweight or obesity and without diabetes demonstrated a safe and tolerable profile in line with the drug receptor classes, and with notable reductions in body weight.
They add: “A single molecule that targets both amylin and GLP-1 biology in a tablet form could offer a more convenient approach to achieving better outcomes for individuals with overweight or obesity.
“However, larger and longer studies are needed to fully assess the drug’s safety profile and potential.”
Meeting:
Annual Meeting of the European Association for the Study of Diabetes (EASD)
Assuming an initial body weight of 220, this is over 1000 cal per day deficit under BMR. That’s a bunch. While the result is impressive, what happens next?
Percent of muscle mass / fat?
One notices "...developed by the Danish pharmaceutical company Novo Nordisk." That company's other drug which sells so well through aggressive marketing in the US is banned from sale in the EU, as dangerous to health.
Here's a novel idea. Buy no over-processed, sugar stuffed foods. Eat fresh and buy local produce. Stay active and stay away from corporate seductions for "weight loss."
I have lost 70 pounds in 2 years by eating less. I now get full on half the food I used to eat. Didn’t really cut out anything, just less at each meal. I just ate slower and quit when I felt full.
IIRC, when the body runs out of fat to convert to energy, it starts converting muscle mass.................
Have you or a loved one been harmed or possibly died as result of using the weight loss medication Amycretin? Then you could be eligible for a massive settlement. Just call Dewey, Cheatum and How
Go read market-ticker.org today.
Warning: language.
You don’t lose weight to get healthy. You get healthy to lose weight.
Good on you!
Fast weight loss results in sagging skin ... and sagging skin cannot be unsagged.
Market Ticker is always a must read. As for language? Don’t throw the baby out with the bath water...if you’re easily offended, stay off the internet.
Wegovy (another weight loss drug) states plainly that after the weight loss, if the patient discontinues the drug, the weight comes right back. So, you’re on it for life (however short that may be).
No kidding. I was just about to post how scary this latest one sounds....like the other ones.
Non-stop ads, on any tv program.
Just eat right (as you say, good, clean foods...no processed foods, we also cut out grains) and exercise/keep moving!
There is that possibility.
Excellent. You’ve done by natural means what others feel they need drugs for in order to do.
It seems, from what little is in this news report, that the drug targets the appetite sensation, so that the users aren’t as hungry, so that IF THEY WANT TO EAT LESS AND DO SO, they can take in fewer calories to aid their overall weight loss plan. They still could CHOOSE to eat and overeat and not exercise, etc., unless they have some uncontrollable urges forcing them to eat eat eat.
Maybe they need to combine an anti-OCD drug with this new class of drugs, and an anti-depressant, and a stimulant, oh, and more drugs to counter the side-effects of those drugs and their side-effects. Yes, that’s the ticket.
Hmmmm, I need to speak to my stock broker.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.